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Physiology and Disease
Theo Borgovan, Lorin Crawford, Chibuikem Nwizu 
and Peter Quesenberry
Abstract
This is an extraordinary time in cell biology with evolving data pushing a recon-
sideration of the stability of cell systems and the regulatory mechanisms underlying 
cell phenotypes, especially the functional cell phenotypes. In this chapter, we will 
explore new insights into stem cell and extracellular vesicle biology with a focus on 
the role of extracellular vesicles in normal stem cell physiology as well as in vari-
ous disease states. Extracellular vesicles (EVs) are being recognized as influential 
mediators of cellular function and potential experimental therapeutic strategies 
for a number of disorders outlined in this review. An evolving paradigm indicates 
a dynamic flux of EV populations within these disease states. We conclude our 
discussion of EV by extending our knowledge of robust EV biology toward disease 
detection and prognostication. Characterizing the biophysical and functional 
changes of vesicles amid disease progression or regression enables investigators to 
merge this information flux with existing deep learning computational and statisti-
cal techniques—allowing knowledge to be abstracted from large data sets profiling 
the biology of EVs within various disease states. Understanding how EV population 
shifts represent disease regression or progression creates paramount potential for 
EVs as salient and clinically relevant diagnostic and prognosticating tools.
Keywords: stem cell continuum, extracellular vesicles, deep learning, biomarkers
1. Introduction
In many traditional stem/progenitor models for different tissues the generally 
accepted models have posited a primitive stem cell giving rise to more differenti-
ated progenitors and finally terminally differentiated end cells, which may or may 
not retain the capacity for cell division. Perhaps the most intensively studied stem 
cell system has been that of the hematopoietic stem cell [1–6]. In general, current 
dogma has it that the long-term repopulating hematopoietic stem cell is a dormant 
non-cycling cell characterized by a surface phenotype that is negative for conven-
tional differentiation markers (B220, Gr-1, Mac-1, Lyt-2, L3T4 and Ter119) and 
positive for c-kit, Sca-1 and CD150. It is felt that this cell can be purified by FACS 
and that in response to various differentiating stimuli it progressively differentiates 
into different lineage restricted populations, which in general are actively cycling. 
A large number of studies have extensively characterized its molecular regulation 
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and biologic characteristics [6–11]. We began studying both purified stem cells and 
unseparated whole marrow stimulated to progress through cell cycle with cytokine 
exposure and demonstrated that there were cycle related and reversible changes 
over time in long and short term engraftment, progenitor levels, differentiation into 
megakaryocytes and granulocytes, homing to marrow, capacity to alter phenotype 
toward lung cells in response to pulmonary derived extracellular vesicles (EVs), 
overall gene expression, capacity to take up vesicles and circadian characteristics 
[12–22]. Passegue and colleagues [23] studied lineage negative Sca-1+ c-kit+ and 
thy+/− stem cells further separated into G0, G1 and S/G2/M fractions as to long-
term engraftment into lethally irradiated mice. They found that all engraftment 
capacity was in the G0 population. This indicated that our observations might be in 
vitro artifacts. However, we noted that no one had adequately studied unseparated 
marrow as to the cycle status of long-term repopulating stem cells. We essentially 
reproduced the Passegue data studying purified stem cells, but when we studied 
unseparated whole marrow we found that over 50% of the long-term engraftable 
cells were in the S/G2/M fractions. In order to address the potential problem of cel-
lular cross contamination in the FACS experiments we utilized a thymidine suicide 
technique in which cycling cells are selectively killed by a 30-minute exposure 
to high specific activity tritiated thymidine. Studies here showed that anywhere 
between 70 and 100% of the long-term engrafting stem cells were in S phase at the 
time of the incubation. Further work using in vivo BrdU indicated that the dormant 
purified stem cells (Lin-C-kit+Sc-1+) rapidly progressed through the cell cycle such 
that up to 85% of them showed the BrdU label by 48 hours of in vivo BrdU expo-
sure. These data showed that a large number of HSC in the mouse are actively pro-
liferating and thus always changing phenotype. When lineage positive and lineage 
negative marrow cells were assessed for engraftment and cycle status, it was found 
that a large number of marrow stem cells were in both fractions and were cycling 
[24]. In further work, we have shown that different lineage positive cells are rich in 
cycling stem cells, but intriguingly when double sorted that lineage positive cells 
no longer showed HSC characteristics but there was a separate population negative 
for the particular marker with enriched and cycling HSC. This data has led to our 
current hypothesis that hematopoietic stem cells exist on a cycle related continuum 
and that these cells while maintaining critical stem cell markers show cycle related 
fluctuation in differentiation markers [22]. We feel that we may be defining the 
calculus of hematopoietic stem cells with time and cycle related phenotype changes 
being the derivatives and with the final overall picture the integral.
Whether this model of small incremental cellular changes over time applies to 
other stem cell systems will clearly be the object of much future work.
The stability of cell types and systems is also up for grabs. Early in the study 
of hematopoietic stem cells Till et al. [25] showed that the first stem cell assay, 
the colony forming unit spleen, showed marked heterogeneity but the assay was 
generally reliable. They compared the CFU-s system to radioactive isotopes; the 
individual decay rates were totally heterogeneous, but the overall half-lives were 
reproducible and quite exact. These data would indicate the potential importance 
of evaluating the total population of stem cells alongside the purified variety. 
The variable and shifting phenotypes of the stem cell with cell cycle transit 
has to be considered in the context of extracellular vesicle modulation of cell 
phenotype.
1.1 Extracellular vesicles
Tiny lipid membrane enclosed particles are released from essentially all cell 
types in the mammalian body [26, 27]. These entities were first found to come 
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from red blood cells and platelets and felt to be essential cellular waste products 
[28, 29]. Subsequent work has characterized and subdivided these entities to size, 
density and morphology. Eventually two basic types of vesicles were defined by 
differential ultracentrifugation; exosomes and microvesicles. Exosomes derived 
from multivesicular bodies were from 30 to 100 nm in diameter while microves-
icles derived from membrane blebbing were from 100 to 1000 nm in diameter. 
Other vesicular entities were also defined including apoptotic bodies. In general, 
there was much overlap between exosomes and microvesicular bodies and a meet-
ing of investigators decided it might be best to simply term these as extracellular 
vesicles (EV) and then define their source and the conditions under which they 
were isolated. Vesicles were eventually isolated from virtually all bodily fluids 
and cells [26, 27]. Recent focus has been on the capacity of EV to restore injured 
tissue and treat disease. Initial work showed that vesicles could transfer protein 
and RNA while modifying the phenotype of cells and reversing disease in animal 
models.
Ratajczak et al. showed that embryonic stem cell derived microvesicles could 
reprogram hematopoietic progenitors by horizontal transfer of mRNA and protein 
delivery [30]. This was followed by work by Aliotta et al. [31–33] and Valadi et al. 
[34] showing RNA transfer and phenotype change in different experimental mod-
els. Further work has indicated that cellular phenotype change may be mediated by 
transfer of transcriptional activators possibly miRNA [35]. Vesicles from different 
sources are different but do contain some features of their originating cells. Vesicles 
contain protein, mRNA, miRNA, lipids and variably DNA, thus they represent 
complex bio machines with a tremendous range of potential phenotype altering 
messages.
1.2 Hematopoietic stem/progenitor cells
Vesicles have been found to have a variety of effects on both normal and dis-
eased or injured tissues. These effects may be negative or positive depending upon 
the specifics of the experimental models under consideration. In many instances 
there appears to be a yin/yang nature to vesicle effects. Studies with murine marrow 
cells have illustrated the complexity of vesicle marrow cell interactions [26, 27]. 
Early studies showed that ES derived vesicles could improve proliferative status of 
lin-Sca-1+ marrow stem cells [30] and work in our laboratory has shown that lung 
derived EVs could induce expression of surfactant A, B, C and D, Clara cell protein 
and aquaporin in normal murine marrow cells [31–33]. Studies indicated that for 
a genomic change to occur the vesicle had to enter the target marrow cells [34] 
and that initially both mRNA and a transcriptional regulator were transferred to 
target cells but that the transferred mRNA was degraded and long-term expression 
of surfactants B and C (those tested in these studies) derived from the target cells 
and represented a stable epigenetic event [35]. The functional effects of vesicles on 
marrow mRNA expression depended upon the cell cycle status of the target mar-
row cells and the condition of the originator lung cells, in this case either irradiated 
or not [21]. The results showed that Lin-Sca-1 murine marrow cells showed peak 
pulmonary epithelial cell-specific mRNA expression in cell cycle phase G0/G1 when 
the vesicles were derived from irradiated lung tissue while the peak was in late G1/
early S phase when the vesicles were derived from nonirradiated lung. Vesicles were 
present in all types of differentiated marrow cells. Vesicles demonstrated a capacity 
to reverse radiation damage to marrow and gastrointestinal tissues of mice with the 
most impressive effect being on long-term engrafting stem cells [36]. The vesicles 
were shown to increase proliferation, decrease apoptosis and reverse double-strand 
DNA breaks.
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2. EVs and implications on selected disease states
In the following section, we discuss the role of EVs in various disease states, as 
well as their role in disease detection, progression, and treatment.
2.1 Pulmonary hypertension
The yin/yang vesicle effect is clearly illustrated by studies on murine models of 
pulmonary hypertension.
There are two major models of murine pulmonary hypertension; the monocro-
taline treated mouse [37] and the Sugen/hypoxia treated mouse [38]. These may 
represent different forms of pulmonary hypertension but results with different 
vesicle populations have been similar in both models. Work with the monocrotaline 
murine model has shown that vesicles in the serum or from the lungs of mice with 
monocrotaline induced pulmonary hypertension will induce pulmonary hyperten-
sion when injected into normal mice [39]. Further work has indicated that marrow 
from these mice with PH will induce PH in normal irradiated mice [40]. It appears 
that vesicles from damaged lung tissue, probably damaged endothelium, travel to 
marrow and induce an endothelial to hematopoietic transition (EHT) with produc-
tion of “toxic” endothelial progenitors which travel back to the lung, differentiate 
into pro inflammatory macrophages and induce vascular remodeling resulting in 
pulmonary hypertension [41]. Marrow derived mesenchymal stem cell (MCS) 
derived extracellular vesicles were shown to either prevent or reverse pulmonary 
hypertension in both rodent models [39]. As the endothelial progenitors are quite 
radiosensitive low dose was tested as a potential therapy for pulmonary hyperten-
sion. One hundred cGy whole body irradiation both prevents and reverses pulmo-
nary hypertension in these models. This is the second potential therapy. The EHT is 
regulated to a large extent by the transcriptional factor Runx-1. A Runx-1 inhibitor, 
RO5-3335 has been investigated in leukemia. Here we have shown that the Runx-1 
inhibitor Ro5-3335 blocks the EHT and reverses pulmonary hypertension in the 
rodent models [41]. Thus, three potential therapies have evolved from extracellular 
vesicle research.
2.2 Vesicles in renal disorders
Dr. Giovanni Camussi and colleagues have carried out a series of ground 
breaking studies on MSC-vesicle effects in murine models of kidney injury. 
They demonstrated that MSC-vesicles could stimulate proliferation and dimin-
ish apoptosis of injured kidney cells [42, 43]. Human mRNAs were transferred 
and translated into proteins in renal epithelial tubular cells of kidney injured 
mice. They studied cisplatin treated mice with acute kidney damage. Here they 
found a dose related correction of injury and felt the therapeutic action was 
related to the antiapoptotic effect of the MSC-vesicles. They also investigated a 
ischemia-reperfusion model of kidney injury and showed that the injury could 
be prevented by a single infusion of MSC-EV [44]. These workers also demon-
strated that the active vesicle population were the smaller exosomes as opposed 
to microvesicles [45].
2.3 Lung cancer
Being one of the most common, and increasingly deadly cancers in the world, 
lung cancer lends itself to early screening mechanisms, as well as the potential clini-
cal value EVs may hold in diagnosing and treating neoplastic disease [46, 51, 52, 54]. 
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Exosomal nucleic acid (such as microRNAs) released from neoplastic lung cancer 
cells play a vital role in cancer’s ability to evade immune response. These cancer-
derived exosomes have been shown to have a critical impact on disease progression 
via their ability to modulate gene expression post-transcriptionally [47, 50]. Lung 
cancer derived exosomes are laden with, and shuttle a vast array of immune sup-
pressive cargo that stymie the function of immune cells. Interestingly the protein 
and nucleic acids carried in these tumor-derived exosomes is similar to those of 
the parent cell it was derived from, allowing for an effective mode of non-contact-
dependent cellular manipulation which has wide reaching implication on cancer 
immune evasion and metastasis.
Vesicles can also have direct actions on target cells. Tumor-associated antigens 
are also loaded into, and perhaps found bound to the surface of many of these nano-
lipid carriers, which can then go on to directly modulate immune mediators’ cellular 
function [47, 71, 73, 74, 86].
EVs shed from lung cancer have also had various implications on the tumor 
microenvironment and phenotype, a phenomenon observed across numerous 
cancer types including leukemia [67]. Vascular endothelial growth factor (VEGF) 
has often been studied as a potential drug target to quench the growth of localized 
and distant lung cancer. Certain monoclonal antibodies that target VEGF are used 
to inhibit the formation of new vasculature often initiated by growing cancer cells, 
which in essence starves a growing tumor from oxygen and other vital nutrients 
[49]. Work by Azmi has shown how a selective population of EVs allows sensitive 
lung cancer to escape these treatments. Tumor cells threatened by an increasingly 
more hypoxic microenvironment secrete a very select population of adapted EVs 
which can directly stimulate the formation of new blood vessels as well entire 
organelles, including mitochondria, allowing for a more efficient biochemical 
use and energy production within an oxygen depleted microenvironment [50]. 
Other works have confirmed this showing that STAT3-regulated exosomal miR-21 
enhances the level of VEGF.
Hypoxia and other cellular stressors can also drive numerous cellular adapta-
tions in lung and other cancers. Hypoxia, acidosis, an immune response initiation 
such as with endotoxin promotes tumor cells to secret more oncogenic EV—these 
cancer-derived exosomes have direct toles in mediating metastasis; perhaps being 
implicated in early cellular dysregulation in order to establish a pre-metastatic niche 
for future metastatic cells [53].
There is direct evidence for the involvement of exosomes from highly metastatic 
cancer cells in educating stromal cells and altering the cancer microenvironment. In 
addition, much of the stromal microenvironment that is exposed to cancer under-
goes mesenchymal transition (EMT), allowing for the genesis of a more aggressive 
phenotype via an EV-mediated process [55]. Rahman et al. found that exosomes 
derived from patients with lung cancer induced vimentin expression, and subse-
quent EMT in normal lung epithelial cells [56].
Lung cancer derived exosomes promote cancer survival via a myriad of other 
mechanisms, including fibroblast growth to enhance desmoplastic stromal 
response which has been shown to enhance tumor growth and block drug delivery 
in lung, breast and pancreatic cancer models. In addition, tumor cell derived EVs 
can sequester and carry bioactive Fas ligand (FasL) which has a role in inducing 
immune cell death, thus dampening the T cell immune response and progressing 
metastasis in lung cancer [57].
Prior work has explored the effect of EVs from lung and bone marrow sources, 
and demonstrated that once at the effector cell, EVs impart cellular effects by 
several purported mechanisms including: (i) direct binding and activation of 
cell surface receptors by proteins and lipid ligands, or (ii) fusion and uptake 
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(phagocytosis/endocytosis) of vesicle contents into the recipient cells. Effector mol-
ecules (e.g., mRNA), non-coding regulatory RNAs (e.g., microRNAs or miRNAs), 
proteins, and transcription factors can all be delivered, each having short- and long-
term implications on effector cell phenotype and function [58, 59]. As discussed, 
various other studies have also highlighted the ability of EVs to directly transfer 
relatively larger molecules such as cellular receptors, major histocompatibility 
complex (MHC) molecules, antigens, as well as entire organelles, some containing 
fully intact mitochondria, lysosomes, Golgi and intermediate filaments [60].
2.4 Breast
EV studies relating to both breast and prostate cancer highlight many of the 
salient principles observed in lung cancer studies, and also exhibit the promising 
roles that EV play in evolving chemoresistance. As we will come to see across a 
variety of cancer models and disease states, EV function carries great plurality-
exhibiting multiple, and often times contradictory effects depending on their 
cellular origin and physiological state [48].
In breast cancer, while healthy mammary epithelial cells within the breast 
stroma secrete EVs that prevent the release of breast cancer derived EVs, the EVs 
shed by the disease cells promote the opposite, imparting an immense impact 
on chemoresistance. Cancer derived EVs are known to shuttle pro-oncogenic 
proteins and nucleic acids from diseases cells to surrounding healthy stroma and 
connective tissue [61]. Zhou et al. reported that breast cancer secreted exosomes 
are enriched in particular RNA species, such as miR-105, which destroys the 
vascular endothelial barrier, allowing cancer to enter the circulation and spread 
[62]. Studies employing fluorescently labeled miRNA-loaded EVs showed that 
tamoxifen resistant breast cancer cells in vitro can carry multiple miRNA profiles. 
EVs packed with fluorescently-tagged miR-221/222 can also shuttle their cargo 
to sensitive cells of the same type, thereby transferring resistance RNAs which 
effectively reduced gene expression of P27 and estrogen receptor-α (ERα) in 
target cell. The loss of p27 has been linked to drug resistance, as it is able to take 
a cell that is arrested in its cell cycle and stimulate its reentry back into active 
cycling [63]. However, as discussed, healthy stromal cells counteract the effects 
of oncogenic vesicles. This competition between “good” and “bad” vesicles is a 
fine balance; a yin/yang that loses equilibrium as cancer overwhelms healthy 
stoma. When stromal cells are outcompeted and significantly influenced by 
oncogenic EV signaling, the now altered stroma in turn activates STAT1 and 
NOTCH3 signaling in breast cancer cells, promoting cancer initiating cell popula-
tions responsible for drug resistance and nascent tumor formation [64]. This is a 
common theme in EV-mediated cancer progression which we will see is universal 
across numerous solid and hematological cancers.
2.5 Prostate cancer
Human bone marrow mesenchymal stem cell (MSC) derived EVs are involved 
in the modulation of cell signaling, cellular differentiation, and proliferation—and 
this is seen across multiple disease paradigms. These regenerative EVs have been 
shown to reverse the malignant phenotype in prostate and colorectal cancer, recov-
ering function in a murine model of AKI, as well as mitigating radiation damage to 
marrow [36]. In models of prostate cancers, the reversal of taxane resistance and 
tumorigenic phenotype in a human prostate carcinoma cell line (as well as human 
explants) can be accomplished by treatment with healthy MSC-derived EVs [61]. 
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Other populations of “therapeutic” EVs (outside of the bone marrow) have also 
been isolated and applied: EVs isolated from normal prostate cells acquired via 
patient biopsy reverse the resistance of malignant prostate cells to various drugs. On 
the contrary we have shown that EVs derived from cancerous cells can drive cancer 
progression and enhance resistance to certain chemotherapies, which again high-
lights the specificity, plurality, the yin/yang of EV functionality [61]. Panagopoulos 
et al. confirmed much of this work, showing that vesicles from both in vivo prostate 
cancer cell and explant cultured prostate cancer cells can induce cellular changes 
that produce a neoplastic phenotype in normal prostate cell lines [65]. These results 
were also reproduced using vesicles from patients with other malignancies, namely 
prostate, and lung [59].
2.6 Neural-derived EVs in traumatic brain injury
Our group has developed a unique biomarker system focusing on EVs isolated 
from the saliva of patients who have experienced mild traumatic brain injury 
(mTBI) [66]. Rather than conventional human serum isolation, this has been a 
novel protocol allowing for the easily accessible collection of saliva laden with EVs 
that have freely trafficked from injured brain parenchyma into the saliva—allowing 
for a representative sample which captures the shift of various EV populations and 
cargo following brain trauma. EVs are membrane bound, and thus are not subject 
to the same degradation that conventional serum biomarkers face, making them 
ideal biomarker candidates. Salivary EVs in particular can be isolated based on 
tissue specificity and have well established roles in the detection of numerous other 
disease states, including oral squamous cell carcinoma [79]. Bolstering their utility 
as a unique biomarker, upon analysis and characterization of patients that had sus-
tained mTBI it became apparent that EVs isolated from saliva had numerous neural 
markers on them, confirming their origin from brain parenchyma [66]. Following 
analysis of the expression of Alzheimer disease (AD) genes in patients who had suf-
fered mTBI vs. healthy controls, multiple important AD specific genes were signifi-
cantly upregulated in patients that had suffered mTBI when compared to healthy 
controls; allowing for the identification of mTBI-specific genetic profiles derived 
from neural derived EVs. The potential characterization of early mTBI biomarker 
genes, including (but not limited to) CTSD, CDC2 and casein kinase (CSNK1A1) is 
being explored [66]. Longitudinal analysis of these patients coupled with further 
analysis of the identified surrogate markers allows for possible prognostication of 
mTBI patients in regard to severity of post-TBI concussion symptoms, chronicity of 
symptomology and potential recovery. This is all made possible by the ubiquitous 
and specific nature of EVs.
2.7 Hematologic malignancies
EVs secreted by blood borne hematologic cancer have modulating affects 
impacting a variety of cancer hallmarks. EVs have a direct effect on phenotypic 
and genotypic changes, highlighting the central role of EVs in the progressions and 
reversal of hematologic malignancies.
2.7.1 Impact on various leukemias
Pathways involved in angiogenesis have been shown to modulate cancer pro-
gressions and chemotherapeutic evasion in multiple models [61]. Vesicles shed 
by chronic lymphocytic and myelogenous leukemia (CLL, CML) transmit cargo 
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containing a myriad of cancer-inducing factors, such as rapamycin/p70S6K/
hypoxia-inducible factor-1α axis. Similar to lung cancer-derived EVS, these CML-
derived vesicles have been shown to bolster the survival of CML B-cells via the 
establishment and proliferation of vascular endothelial growth factor within the 
forming leukemic bone marrow stromal cells [67, 69]. In multiple myeloma (MM) 
models, bone marrow stromal cell-derived exosomes, mediate cellular communica-
tion by transferring mRNAs, miRNAs, and proteins important in proliferation, 
survival, and chemoresistance [77]. Experiments utilizing in vivo mouse K562 CML 
cells showed that neogenic angiogenesis can be induced by immortalized myelog-
enous leukemia cell line K562 exosomes, as well as neogenic changes in human 
umbilical endothelial cells [69].
Other hematologic malignancies show similar cancer induction potential. CML-
derived EVs given to rat models can induce CML-like characteristics via the transfer 
of their oncogenic cargo [67]. Bone marrow stromal cells respond to this influence 
by producing interleukin (IL)-8 (mRNA and protein), a potent pro-angiogenic fac-
tor that modulates both in vitro and in vivo the leukemia cell malignant phenotype 
[67]. In our own established acute myeloid leukemia (AML) model, we explored 
the potential of human bone marrow MSC-derived EVs as a direct adjunct therapy 
for AML. Our studies indicated that the killing potential of cytarabine, at even 
relatively low doses, is potentiated by the addition of healthy MSC-derived EVs. We 
believe EVs can also alter a cancer cell’s sensitivity to chemotherapy via EV guided 
horizontal information transfer. This has implications directly on the cell itself but 
likely also impacts the surrounding stroma in order to further promote oncogenic 
growth and drug resistance of leukemia cells [68]. In models of MM when marrow 
MSC-derived exosomes are cultured with cancerous MM cells, there is a significant 
increase in multiple anti-apoptotic pathways which promoted MM cell viability. 
These exosomes, derived from stromal cells within a microenvironment amidst 
developing active cancer, were also able to induce drug resistance to the proteasome 
inhibitor bortezomib via activation of several survival relevant pathways, including 
c-Jun N-terminal kinase, p38, p53, and Akt [97].
2.7.2 Impact on chemo-resistance
Cancer derived EVs play a central role in facilitating the escape of cell death, by 
cancer cell. Proteins such as BCL-2, MCL-1, BCL-X, and BAX as well as other cell 
death-related proteins were shown to be more concentrated in the EV of apoptosis-
resistant primary AML blasts than EVs from more sensitive AML cells [70]. Via 
confocal-microscopy-based colocalization studies, the direct transfer of EVs from 
resistant to sensitive cells has been observed. Leukemia derived EV harbor multiple 
bioactive lipids, proteins and miRNAS important in chemoresistance. Ibrutinib is a 
drug used clinically to combat leukemia. Analysis of plasma samples collected from 
CLL patients showed exosomes bearing unique micro-RNA prolife, including miR-
29 family, miR-150, miR-155, and miR-223, showed a different exosome profile 
from what is seen when disease is suppressed with ibrutinib treatment—perhaps, 
indicating the potential pathophysiology by which cancerous EVs impart resistance, 
as well as creating a potential for biomarker identification [75]. EVs packed with 
miR-221/222, from tamoxifen resistant MCF-7 breast cancer cells, can shuttle their 
cargo to sensitive cells of the same type, thereby transferring resistance.
2.7.3 Impact on the cancer microenvironment
Healthy bone marrow stroma likely functions to maintain and protect healthy 
bone marrow stroma from nascent cancer. At first detection of threat, the bone 
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marrow microenvironment and residing cells, such as MSCs, combat early cancer—
much of this is likely EV mediated. Our established leukemic cell model has estab-
lished this hypothesis, indicating that MSC-EVs impart a robust anti-proliferative 
and pro-apoptotic effect on leukemic cells in vitro. We also have preliminary data 
using EVs toward clinically relevant endpoints, and have showed they serve as a 
synergistic adjunct to conventional AML therapies, such as cytarabine.
As discussed, the bone marrow stroma can be recapitulated by active cancer 
via multiple EV-dependent mechanisms. Leukemic models have shown the net 
effect of EV-modulation translated to a phenotypic change of the bone marrow 
stromal cells toward a more inflammatory signature that resembles the pheno-
type of cancer-associated fibroblasts (CAFs) [72]. CAFs show enhanced prolif-
eration, migration, and secretion of inflammatory cytokines, all contributing to 
a tumor-supportive niche [72]. As a result, stromal cells exposed to a leukemic 
EVs are not killed but “reprogrammed” to be pro-oncogenic and support tumor 
growth. As discussed, EV populations change depending on disease state [48]. 
In the case of CLL, as leukemic cancer cells progress varying EV populations 
establish control within the microenvironment. CLL-derived EVs rapidly deliver 
their biologic cargo to the surrounding stromal cells, and promoting CAF phe-
notypes with enhanced proliferative and migratory properties [72]. CLL models 
have shown that CAF-derived factors may also have an immunogenic effect on 
the T and myeloid cells, altering their phenotypes into immunosuppressive and 
tumor-promoting Th2/M2-like cells, respectively. These modifications lead to 
defective T-cell and myeloid cell immune responses and an inflammatory milieu 
characteristic of CLL promotion [75].
Leukemic EVs impart genotypic and phenotypic effects on all components of the 
leukemic microenvironment. The bony endosteal compartment of the bone marrow 
niche, composed of osteocytes/osteoblasts/osteoclasts, is reprogrammed by AML—
derived EVs toward inflammatory myelofibrotic cells. These cells support leukemic 
growth and support BM fibrosis, a well-established risk factor for leukemia [75]. 
Metastasis is crucial to cancer survival. Leukemia derived EVs have also been shown 
to disturb the architecture of multiple tight junction proteins in cells of the base-
ment membrane, allowing cancer to detach, mobilize, and metastasize beyond in 
situ disease. Leukemic EVs can also bolster angiogenesis [75]. In vitro studies, first 
reported by Umezu et al., clearly showed leukemic cell to endothelial cell com-
munication via exosomal miRNAs by fluorophore signaling localization, allowing 
for the creation of new blood vessels to feed cancer growing in newly seeded 
microenvironmental niches [76]. Microenvironment stromal cells have been shown 
to directly take up cargo from EVs fluorescently labeled with GFP. As we’ve seen in 
lung and breast cancer cells, Boelens et al. showed that this cross talk is reciprocal 
and that when stromal cells are influenced by oncogenic EV signaling the stromal 
cells themselves in turn activate STAT1 and NOTCH3 signaling in developing 
cancer cells. This cell signaling in turn leads to cell populations responsible for drug 
resistance and nascent tumor formation [64, 78]. Schepers et al. have shown that 
AML cells (likely via an EV directed mechanism) cause numerous chromosomal 
anomalies and genetic mutations within the surrounding stroma, thereby alter-
ing the biology of the stem cell continuum away from normal hematopoiesis, and 
toward transforming bone marrow stem cells toward immature progenitors that 
will subsequently develop into leukemic blasts or altered cancer-stem cells capable 
of supporting a pro-leukemic environment [75]. The CAF phenotype promoted by 
tumor-derived EVs, has, itself, secondary effects on endothelial cells, increasing 
angiogenesis. The sum and synergy of all of these EV-directed microenvironment 
modulations means the leukemia-modified stroma favors leukemic blast prolifera-
tion while stymieing normal hematopoiesis [69, 76].
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3. Machine learning
In this section, we discuss machine learning (ML) as an emerging scientific 
field of sophisticated algorithms that aid in the understanding of how nonlinear 
interactions between molecular features contribute to disease etiology. Here, we 
give relevant background on how machine learning is used in biology, provide 
a formal and probabilistic specification of the hierarchical architectures imple-
mented by common ML methods (Bayesian deep neural networks), and demon-
strate their power via real data applications. Indeed, a myriad of well-established 
algorithms can be surveyed in detail, but our main goal is to develop a more 
conceptual pipeline on how to use machine learning techniques on individualized 
biological problems.
In the context of our own research interests, we have found vesicle biology to 
be amenable to ML because of (i) the ability to observe millions of vesicles during 
a single study and (ii) the nonlinear nature of downstream vesicle effects. As we 
will show, large sample sizes and the presence of variable interactions are often 
leveraged by ML algorithms to provide high predictive accuracies. We hypothesize 
that these performance gains will lend to a more complete picture of how vesicle 
behavior impacts the overall cellular environment.
3.1 Background and significance
Machine learning is often described as a subarea of artificial intelligence that 
seeks to recognize subtle patterns found within data. It has been noted that the field 
has roots dating back to early work done by Arthur Samuel in 1959 [80]. However, 
despite this long history, only recent technological advances over the past two and 
a half decades have considerably revived interest in ML. With increases in both 
data collection and computational power, the applications for machine learning 
algorithms have become vast and integral parts of our everyday lives (e.g., facial 
recognition, spam detection, etc.)
One explanation for the utility of ML approaches is that they are able to model 
complex structures in data and leverage the detailed information to accurately 
predict or classify unobserved outcomes. Unique to these algorithms is their ability 
to adaptively update themselves (learning) through repeated exposure to new 
observations (a process formally known as “training”) [81, 82]. Intuitively, an 
algorithm should achieve a higher predictive accuracy after training on larger data 
sets: the more possibilities an algorithm is exposed to, the better said algorithm 
becomes at correctly identifying similar complex patterns in heterogeneous popula-
tions [82, 85]. This represents a common tenet about ML theory: the more data the 
better. However, just having data is not always enough. A second tenet is related 
to the strength of signal between the observed data and the scientific question of 
interest. The greater the signal-to-noise ratio, the more amenable the task is to ML 
methodology. In practice, there exists a general relationship between tenets 1 and 
2: the more data one has, the less robust the signal-to-noise ratio must be to achieve 
an acceptable prediction/classification; conversely, a high signal-to-noise ratio will 
compensate for less data. Note that this is obviously not a strict relationship, as 
many have demonstrated ML algorithms to perform well on noisy data sets with few 
observations.
With its growing popularity in the biological literature, the formal connec-
tion between machine learning and more traditional statistical sciences cannot be 
overlooked. Indeed, many current approaches in ML are motivated by prediction; 
however, there are opportunities to pair these tools with fundamental probabilistic 
concepts to improve power for inference-based tasks as well. This is particularly 
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relevant for biological problems where it is also important to understand the 
processes that are contributing to better predictions. To this end, recent works have 
used (interpretable) ML algorithms for live risk stratification in cancer patients [6], 
novel biomarker identification in liquid biopsies [87], hypoxemia prevention during 
surgery [88], point-of-care diagnosis of lymphoma [89], as well as many other uses 
in genetics and genomics [82, 83].
3.2 Probabilistic formulation
With an increasing literature on both statistical and machine learning methods, 
it can be difficult to decide which algorithm to use Figure 1 provides a general 
approach for determining the proper choice [90]. In this section, however, we will 
focus on detailing an increasingly popular machine learning method known as a 
neural network (NN). Although NNs excel at classification tasks (see Figure 1), 
many recent works have focused on applying neural networks to a wider range of 
applications [83, 91, 92].
For simplicity, we will consider an arbitrary data analysis problem. Let  y be an  
 n -dimensional response/outcome vector for  n individuals. Assume that for each 
individual, we measure  p features and tabulate their collection via an  n × p design 
matrix  X . Statistically, these features are variables that we believe will help accu-
rately predict the outcome. In the case of our research on vesicle biology, features 
may be biophysical (i.e., vesical diameter and volume), genomic (i.e., sequence 
data), proteomic, or lipidomic measurements. Following previous work, we may 
specify a (Bayesian) NN by assuming some hierarchical architecture to “learn” the 
predicted response for each observation in the data [96].
Figure 1. 
Basic “decision tree” schematic for deciding between different statistical and machine learning methods. Here, 
approaches are grouped by their designed purpose for applications.
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  y ^ = σ [  f ] (1)
  f = H (θ) w + b (2)
  w ∼ π (3)
These sets of equations reformulate a general NN as a probabilistic hierarchical 
statistical model. In Eq. (1),  y ^ is an  n -dimensional vector of predicted values,  f is an  
 n -dimensional vector of continuous unbounded values that need to be estimated, 
and  σ [∙] is a link function that relates  f to the mean of the (assumed) distribution of  y . 
Note that the link function can be flexibly changed depending on the goals of the 
research. For example, in the case of regression problems with continuous out-
comes, the link function is set to the identity; while for classification-based applica-
tions with binary data, we may use a sigmoid function that which transforms the 
systematic part of the model to be between 0 and 1. If one is faces with a multiclass 
problem, then  σ [∙] can be redefined as a softmax function.
In Eq. (2), we use  H [θ] to denote an  n × k matrix of activations from the pen-
ultimate layer (which are fixed given a set of inputs and point estimates  θ from 
previous layers),  w is a  k -dimensional vector of weights at the output layer that is 
assumed to follow some prior distribution  π (see Eq. (3)), and  b is an  n -dimensional 
vector of biases that is produced during the training phase.
Under this formulation, notice that we may divide arbitrary Neural Networks 
into three components (see the middle panel in Figure 2): (i) an input layer of 
the  p features in the design matrix  X (red nodes), (ii) a set of hidden layers where 
parameters are deterministically computed based off of a set series of activations 
and point estimates (blue nodes), and (iii) a penultimate layer where the weights 
are treated as random variables (green nodes). This structure is also highly gener-
alizable: hidden layers can take on any form, provided that the additional structure 
can be represented via some linear combination of activations, weights, and biases.
Figure 2. 
Our general work flow for when using neural networks for prediction purposes in biological datasets. Here, we 
show how diverse feature types can be transformed/quantified and used for various applications.
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3.3 Real data applications
We now demonstrate how machine learning and, more specifically, neural 
networks can be adopted to positively impact data analysis. Our group looks to 
characterize the vesicle phenotype of patients at various stages of treatment in vari-
ous leukemias, such as AML. Here, we utilize a common NN architecture known 
as a Multilayer Perceptron [84] where we first train the algorithm on patients with 
known disease statuses (i.e.,  y i = 1 if the  i th patient has cancer) and then test its 
ability to accurately classify a set of undiagnosed individuals. We define accuracy 
here as simply the percentage of correctly classified samples in a testing dataset. For 
each validation run, a Receiver Operating Characteristic (ROC) curve is drawn and 
the area under the curve (AUC) is calculated. The AUC is a standard performance 
metric for classification problems in statistics and may be interpreted as an assess-
ment of how effective an algorithm is at discriminating between two classes (i.e., a 
healthy versus a disease phenotype) [93]. Higher AUC values (on a scale from 0 to 
100%) indicate better model performance. An overall summary of our workflow 
may be found in Figure 2 where we illustrate how different biological features are 
quantified and few through a NN to make predictions.
We first trained the algorithm on data collected from a NanoSight Tracking 
instrument, the NS5000. This allowed us to collect a wide selection of vesicle 
features including size, area, volume, diffusion coefficients, and total vesicles 
secreted. This data was collected from two cell type populations: (i) a primary 
hMSC cell line and (ii) a Kasumi AML cell line. We did this in order to first assess 
the validity of the idea that there is a discernable difference between vesicles 
derived from “normal” hMSC and vesicles from the cancerous Kasumi cell line. 
Within the training set, we were able to classify vesicles with relatively high 
accuracy: the mean AUC (plus or minus standard deviation) after 10-fold cross 
validation was 90.16 ± 9.26%. This translated into a high accuracy in the testing 
population with a mean AUC (after 10-fold cross validation) of 95.97 ± 5.38%. 
We next tested the algorithm on real patient samples, achieving perfect accuracy 
in reliably characterizing and classifying healthy tissue. We believe the reason for 
the high accuracy is due to the primary hMSC cell line accurately representing the 
vesicular phenotype of normal, healthy bone marrow. There is still some work to 
be done in accurately classifying malignant samples. We believe that the heteroge-
neity of the leukemic vesicle phenotype cannot trivially be captured through cell 
line data [94, 95].
To address this heterogeneity problem, we then elected to train and test our 
machine learning algorithm solely on patient samples—in hopes of increasing 
the predictive performance. We fed the model 35 samples from patients with 
various hematologic conditions. We tested and trained the model on these 35 
samples and were able to achieve a mean training accuracy of 93.76 ± 4.77% and 
an out-of-sample AUC of 97.33 ± 3.46%. The high testing performance suggests 
that the algorithm is capable of accurate classification and serves as a general 
proof-of-concept of the potential utility of machine learning in this space. Here, 
this technology has the power to identify complex, heterogeneous patterns 
that distinguish the normal healthy vesicle phenotypes from leukemic vesicle 
phenotypes.
4. Conclusion
EVs are a ubiquitous and dynamic population of cell-specific information. 
Functionally, they act as a class of membrane-bound cellular communication 
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particles that contain bioactive molecules. By exerting their effects through RNA, 
proteins, lipids and variably DNA, EVs implement various downstream phenotypic 
and genotypic effects across multiple disease states. By enabling contact-free 
cell to cell communication, EVs can modulate normal physiological homeostasis. 
Moreover, research has shown that certain subpopulations of EVs are responsible 
for initiating and maintaining certain pathological states. This is the “Yin and Yang” 
of vesicle biology which posits that EV populations harbor a functional endpoint 
specific to cell type and disease state. There are far reaching implication in utilizing 
EVs toward clinical endpoints focused on disease identification, progression, modu-
lation, and ultimately cures.
In order for EVs to be effectively utilized in the identification, prognostication, 
modulation, and curing of disease, more work needs to be done with regards to 
understanding the nonlinear effects of EVs on target cells. Enter the need for novel 
and sophisticated statistical modeling techniques. The steadily increasing size of 
“omic” data sets, along with significant improvements in computational power 
and machinery, has caused resurging interest in machine learning. Consequently, 
this revival has led to algorithmic improvements in both predictive accuracy and 
precision. With the large amount of information that EVs provide, there is a unique 
opportunity to gain new knowledge from applying ML techniques to current 
problems focused on better understanding complex EV biology.
Our lab has already begun utilizing ML algorithms in the characterization of dis-
eased subpopulations of EVs. Currently, most active areas of research in vesicle biol-
ogy focus on characterizing EVs via isolation methods. Alternatively, we propose 
to analyze entire populations of EVs jointly, for we believe a wholistic view better 
captures the true nature and variability of a patient’s disease process. Thus, our 
work is novel in this respect: we use predictive algorithms to identify subtle patterns 
within a given vesicle population. Here, we analyze how particular subpopulations 
interact and detail how these interactions influence the underlying disease process. 
Furthermore, we hypothesize that by monitoring a patient’s entire population of 
EVs throughout the course of treatment, we can better predict the efficacy of the 
treatment. Preliminary results have yielded positive results with respect to catego-
rizing diseased and healthy EV populations. Work now must be done to further 
characterize these subpopulations within the context of specific diseases, such as 
AML and other blood neoplasms. EV biology presents another avenue of utility for 
the field of machine learning. Concatenating large sets of EV information within 
interpretable ML algorithmic frameworks can lead us closer to the use of EVs as a 
predictive and useful clinical marker. Overall, the future is bright for both the fields 
of EV biology and ML.
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